Skip to main content

repaglinide

Generic: REPAGLINIDE·Brand: PRANDIN, REPAGLINIDE

repaglinide: 3 clinical trials tracked.

repaglinide evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about repaglinide, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 3 study sponsors
Clinical Trials (3)

A Phase 1b, Open Label, 2-Part Study to Evaluate the Effect of Pelabresib (DAK539/CPI-0610) on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Patients With Advanced Malignancies

NCT07340190·Phase 1·NVS
Recruiting

Primary endpoint: Maximum Plasma Concentration (Cmax) of repaglinide, midazolam, and drospirenone and ethinyl estradiol

Interventionalopen24 targetStarted 2026-06Completion 2028-046 sites · France, Italy, SpainNovartis Pharmaceuticals

A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625·Phase 1·PMVP
Recruiting

Primary endpoint: Metformin Cmax geometric mean ratio

Interventionalopen14 targetStarted 2026-02Completion 2028-015 sites · United StatesPMV Pharmaceuticals, Inc

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

NCT05384626·Phase 1/Phase 2·NUVL
Recruiting

Primary endpoint: Dose limiting toxicities (DLTs) (Phase 1)

Interventionalopen840 targetStarted 2022-06Completion 2028-0150 sites · Australia, Belgium, Canada, France…Nuvalent Inc.